Disclosed is the use of a MASP-3 inhibitory agent in the manufacture of a medicament for treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), wherein said MASP-3 inhibitory agent is a MASP-3 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:8 and inhibits factor D maturation.